Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
In January, China approved imports of a new genetically modified soybean variety — Enlist E3 soybeans jointly made by Corteva Agriscience, a division of DowDupont and seed company MS Technologies — that can withstand the herbicide 2,4-D. “This is great news for U.S. soybean growers,” said Joseph Merschman, president of MS Technologies in a February press release. “This announcement clears the way for even more soybean growers to experience the high-yielding elite genetics and exceptional weed control offered by the Enlist E3 soybean system.” DowAgrosciences declined to comment for this story. ___ The nonprofit news outlet Midwest Center for Investigative Reporting provided this article to The Associated Press through a collaboration with Institute for Nonprofit News. ___ The herbicide — 2,4-D — was one of the active ingredients in Agent Orange and has been shown to drift miles away from where it’s applied. The U.S. used Agent Orange during the Vietnam War to eliminate crops and forest covers for enemy troops. The International Agency for Research on Cancer named the weed killer a possible human carcinogen. Studies have also linked 2,4-D to endocrine disruption, disturbing estrogen, androgen and thyroid hormones. Over the past two decades, a growing number of weeds have become resistant to glyphosate, the most popular weed killer in the world, sold as Monsanto’s Roundup. In response, agribusiness companies, like Dow and Monsanto, have introduced new genetically modified varieties of soybeans that can be sprayed with other herbicides that kill glyphosate-resistant weeds. The United States exports $14 billion worth of soybeans to China, or one of every four rows of soybeans, annually, according to the American Soybean Association, an organization of soybean producers. Trade tensions with China and higher import taxes on U.S. soybeans have thwarted imports recently. The U.S. Department of Agriculture has projected that increased 2,4-D use due to the Enlist system would likely increase the amount of the weed killer sprayed between 200 and 600 percent by 2020. Already, it’s one of the most commonly used herbicides in the United States, used in conventional agriculture including corn and is one of the most commonly used home and garden herbicides. In 2016, the USDA estimated that farmers used 44.4 million pounds of 2,4-D on crops across the U.S. “This is just going to absolutely be a disaster,” said Nathan Donley, a senior scientist at the Center for Biological Diversity, a nonprofit organization that works to protect endangered species. The Enlist approval gives farmers looking to manage glyphosate-resistant weeds a new tool at a time when the dominant soybean system — Monsanto’s Roundup Ready 2 Xtend soybeans — has caused widespread issues in the Midwest and South. Those soybeans are genetically engineered to withstand being sprayed by dicamba, a volatile herbicide that has drifted off target and damaged millions of acres of non-resistant soybeans, other crops and natural areas since the Environmental Protection Agency approved new versions of the weed killer for use on soybeans in November 2016. More than 90 percent of soybeans grown in the United States are genetically modified, but there are only three major systems that are commonly used to combat glyphosate-resistant weeds: Monsanto’s Xtend, DowDupont’s Enlist and BASF’s LibertyLink soybeans, which are resistant to glufosinate, another herbicide. Enlist soybeans can also be sprayed with glufosinate. The extent to which 2,4-d-resistant soybeans will be planted is unknown, largely because of the widespread market penetration by dicamba-resistant soybeans. Company officials estimated the product will have at least 10 percent market share by 2020, which would be about 9 million acres in the United States. In two years, dicamba went from being sprayed on zero acres of soybeans to more than 40 million acres. Aaron Hager, an associate professor at the University of Illinois, said many farmers have adopted Monsanto’s Xtend soybeans as a protection measure against drift from dicamba. “It’s going to be difficult for (Enlist) to gain market penetration partially because of how well entrenched dicamba already is,” Hager said. The main question for farmers considering Enlist is whether drift from dicamba will damage Enlist soybeans, said Charles Benbrook, a visiting professor at the University of Newcastle who has spent decades studying pesticides at various institutions. “One of the huge questions is, is there any cross resistance? Will they be any less vulnerable to damage from drifting dicamba and vice versa?” Benbrook said. Benbrook said they may be able to coexist. Though 2,4-D and dicamba are different pesticides, their similarities might allow some cross-resistance in genetically modified soybeans, Benbrook said. Both dicamba and 2,4-D have been used for decades on other crops but at a smaller scale. Both are broadleaf herbicides that kill plants in similar ways, mimicking natural plant hormones called auxins and causing abnormal growth. Like the new version of dicamba, the new 2,4-D strain approved for usage on soybeans is designed to be less volatile than past versions. If there is no cross-resistance, Benbrook projected that Corteva, a division of DowDupont, and Bayer, which owns Monsanto, will likely have to come up with a deal to put the resistant genes in both company’s systems, increasing the price for farmers. Donley said both herbicides, having similar modes of actions and a propensity to drift, will insert an element of doubt on what caused drift damage. States across the Midwest and South have received a record number of pesticide misuse complaints from farmers since dicamba was allowed on soybeans. Already, some scientists have speculated that 2,4-D is causing some of the alleged dicamba damage. “Industry is going to use this to say, ‘how do you know it’s our product?’” Donley said. “It’s going to enable the industry to do what they do best, which is sow doubt in the public.” Environmental groups argue the transition to 2,4-D-resistant soybeans, and the increased spraying that goes along with it, is indicative of the problems with industrial agriculture. Jennifer Sass, senior scientist at the Natural Resource Defense Council, an environmental advocacy group, has researched the human health effects of 2,4-D, and said that the herbicide can cause disruptions in the endocrine system. She said that the link to cancer isn’t quite as established. Though 2,4-D is considered a “possible carcinogen,” the research isn’t quite as strong, but that’s because of the difficulties in collecting data, she said. “Those are all data and red flags, but there’s so many reasons to get off this treadmill. Waiting for more confidence in the cancers means waiting for more farmers and pesticide applicators to get cancer, and I don’t think anyone wants to collect our data that way,” Sass said. In some places, some types of glyphosate-resistant weeds, like Palmer amaranth, are already becoming resistant to 2,4-D and dicamba. Bill Freese, a senior scientist at the Center for Food Safety, which is a nonprofit group focused on the environmental effects of food production, said, in addition to human health issues, more spraying will lead to environmental issues, like the killing of pollinators and wild plants, he said. Donley, at the Center for Biological Diversity, has documented those problems with glyphosate and dicamba, especially when it comes to monarch butterflies and milkweed. He said more spraying will lead to more resistance and new herbicides. “It’s a poor answer to a complex situation, and it’s going to be getting worse,” Donley said. “In five-to-10 years, we’re going to be looking for the next herbicide. History tells us what’s going to happen in this case. It’s kind of crazy we’re even considering going here.”

Ex Output:
Last year it was dicamba, this year it’s 2,4-D.


Ex Input:
"The Clinton Foundation might be committed to doing good around the world, but Hillary Clinton’s critics see it as a ripe target to bring down the presumptive Democratic nominee. Republican Donald Trump recently charged that some countries who gave money to the foundation received favorable treatment in return. For anyone who hasn’t heard about the Clinton Foundation, it’s the signature project to reduce poverty and improve global health created by former President Bill Clinton. It is part matchmaker, helping wealthy donors connect with doers, and part active participant, directly running programs, especially in health care. In an interview with Hillary Clinton, CNN’s Anderson Cooper quoted Trump and asked if her husband would break all ties with the foundation, should she become president. Clinton said she would cross that bridge ""if we come to it,"" and proceeded to give a full-throated defense of the foundation. ""I'm proud of the work that it has done,"" Clinton said in the June 8, 2016, interview. ""Nine million people have lower-cost HIV/AIDS medicine because of the work of the Clinton Foundation and my husband. We have women across the country, from Latin America and Africa -- across the world, I mean -- getting good jobs, and being able to support themselves for the first time."" We’ll focus on the first part of that statement and explore if the Clinton Foundation actually had a hand in making HIV/AIDS drugs more affordable for 9 million people? The foundation’s work on HIV/AIDS treatment dates back to 2002 with the creation of the Clinton Health Access Initiative. That was a time when some countries were paying $1,000 or more to treat each AIDS patient. The basic goal was to bring in bulk-buying to lower costs. The program consolidated both the supply of raw materials to make the drugs and the bidding to supply the finished product. The result was lower production costs and lower drug prices. Today, the initiative tracks the going price for a menu of treatments and posts them to help health departments around the world as they negotiate with drug companies. In 2014, the World Health Organization reported that by the end of 2013, more than 11.7 million people were on antiretroviral therapy in low- and middle-income countries. While the kinds of drugs have changed, the WHO said ""in the past decade the price of individual antiretroviral formulations has decreased considerably."" The treatments used in the early days have fallen from a median cost of about $600 in 2003 to about $100 a decade later. A more advanced drug combination introduced in 2005 saw a similar decline. Importantly, the WHO listed the Clinton Health Access Initiative as one of a handful of organizations collaborating on ensuring a steady supply of drugs. The partners in that effort include the biggest players, including several United Nations agencies, PEPFAR (the President’s Emergency Plan for AIDS Relief) and UNITAID, a project created by  Brazil, Chile, France, Norway and the United Kingdom. UNAIDS announced at the end of May that the number of people under treatment is now closer to 17 million. Technically, the Clinton Health Access Initiative has been a separate nonprofit since 2010, but it is still integrated within the Clinton Foundation and the foundation press office still offers comments on its behalf. Clinton Health Access Initiative spokeswoman Maura Daley told us that Clinton used an old figure for the people being served by the initiative. ""The total number of patients benefitting is 11.8 million,"" she told us. Not everyone getting treatment is counted as benefiting from the initiative’s efforts. Beyond working to reduce drug costs, it also coordinates with nongovernmental organizations inside countries to distribute the drugs once they arrive. Clearly, the Clinton Health Access Initiative did not accomplish all of this on its own, but Clinton didn’t say that. Two experts in HIV/AIDS treatment, Jennifer Kates at the Kaiser Family Foundation, and Ellen ‘t Hoen call the initiative an important player. ‘t Hoen was the first executive director of the Medicines Patent Pool, a group that streamlines the production of generic antiretroviral drugs. ""Without the work of the MPP it would have been much harder for organizations like CHAI to access generic antiretrovirals,"" she said. The initiative has been faulted for failing to fully report donations from foreign governments and has filed amended returns for 2012 and 2013. Our ruling Clinton said 9 million people have lower-cost HIV/AIDS medicine thanks to the efforts of the Clinton Foundation and her husband. Bill Clinton started the foundation and its first big project was the Clinton Health Access Initiative. The program focused on using market mechanisms to reduce treatment costs. Costs have fallen dramatically and the initiative remains a key global player in maintaining a steady supply of affordable drugs. If anything, Clinton understated the number of people who have benefited from the program.

Ex Output:
Nine million people have lower-cost HIV/AIDS medicine because of the work of the Clinton Foundation and my husband.


Ex Input:
The suspension of aid work came after unknown assailants fired rocket-propelled grenades at three aid organizations in the southwestern province of Dhale over the weekend, according to the U.N. Humanitarian Office in Yemen, wounding a security guard and damaging several office buildings. The bombings signaled “an alarming escalation in the risks faced by humanitarian workers” and halted the provision of badly needed aid to 217,000 residents, the U.N. statement said. Yemeni officials blamed Islamic extremist groups, noting that al-Qaida’s branch in Yemen has previously attacked aid organizations around Dhale and routinely incites violence against foreign-funded humanitarian programs, accusing them of anti-Islamic activity. The officials spoke on condition of anonymity under regulations. The U.N. humanitarian chief Mark Lowcock condemned “the continuation of media campaigns in parts of Yemen that spread rumors and incitement against aid operations,” compelling them to cut back on crucial work. The International Rescue Committee, a New York-based nonprofit, reported that grenades exploded in its office and women’s center on Sunday night and expressed “extreme concern” for the safety of its local staff. It said the group would restart programs “as soon as it is deemed safe for our staff to return to work.” Militants also struck the Dhale office of Oxfam, one of Britain’s largest charities. “Aid workers should not be a target,” said Muhsin Siddiquey, Oxfam’s director in Yemen. Yemen, the Arab world’s poorest country, has been convulsed by civil war since 2014, when Houthi rebels captured the capital, Sanaa, along with much of the country’s north, driving out the internationally-recognized government. Months later, a Saudi-led coalition intervened to fight the Iran-backed Houthis and restore the government. In the country’s north, the Houthi-run health ministry declared Tuesday that a bout of fast-spreading swine flu had killed 94 people in October alone. Thousands of reported cases have overwhelmed health care facilities already crippled by constant violence, said Mohammed al-Mansour, a senior Houthi health official, warning the death toll would likely rise. A new outbreak of dengue fever has also swept across the country, killing 68 people, including 16 children under five so far this month, he added. The painful disease has re-emerged due to the deterioration of Yemen’s health and sanitation systems. Fighting in Yemen has killed over 100,000 people and set off the world’s worst humanitarian crisis, leaving millions suffering from food and medical care shortages and pushing the country to the brink of famine. ___ DeBre reported from Cairo.

Ex Output:

Aid groups halt work in south Yemen after targeted bombings.